Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 13/20 | 0.61 |
| ▸ | PTH1R | Q03431 | 6/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30378939 | 0.93 | PTH1R (0.60) | IL23RPTH1R | |
| SCHEMBL29791677 | 0.91 | GLP1R (0.62) | IL23RPTH1R | |
| SCHEMBL29429587 | 0.90 | PTH1R (0.64) | IL23RPTH1RKEAP1 | |
| SCHEMBL29350300 | 0.90 | PTH1R (0.64) | IL23RPTH1RKEAP1 | |
| SCHEMBL29706188 | 0.90 | PTH1R (0.67) | IL23RPTH1R | |
| SCHEMBL31243561 | 0.90 | KEAP1 (0.67) | PTH1RKEAP1 | |
| SCHEMBL30002139 | 0.90 | PTH1R (0.63) | IL23RPTH1RKEAP1 | |
| SCHEMBL30262099 | 0.90 | GLP1R (0.62) | IL23RPTH1R | |
| SCHEMBL30277746 | 0.90 | PTH1R (0.56) | IL23RPTH1RKEAP1 | |
| SCHEMBL29710643 | 0.90 | PTH1R (0.65) | IL23RPTH1RKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027179-A1 | ANTI-SYNUCLEINOPATHY PEPTIDE AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-01-29 | — | — | US | claimed |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | AIKIUM INC (US) | 2025-12-25 | — | — | US | claimed |
| CN-116599086-B | Energy storage frequency modulation control method considering new energy power generation and load uncertainty | 上海电动工具研究所（集团）有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-116341385-B | Calculation method of spectral reflectance of blade | 沈阳农业大学 | 2024-11-26 | — | — | CN | claimed |
| US-20240197895-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH MITOCHONDRIAL COMPLEX I DEFICIENCY USING CASPASE-9 SIGNALING PATHWAY INHIBITORS | UNIV COLUMBIA (US) | 2024-06-20 | — | — | US | claimed |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | CureVac SE (DE) | 2024-03-21 | — | — | US | claimed |
| US-20240042015-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. | 2024-02-08 | — | — | US | claimed |
| EP-4267192-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH MITOCHONDRIAL COMPLEX I DEFICIENCY USING CASPASE-9 SIGNALING PATHWAY INHIBITORS | The Trustees of Columbia University in the City of New York (US) | 2023-11-01 | — | — | EP | claimed |
| CN-116981480-A | Anti-synucleinopathy peptides and methods of treating neurodegenerative diseases | 加拿大不列颠哥伦比亚大学 | 2023-10-31 | — | — | CN | claimed |
| WO-2023143464-A1 | FUSION PROTEIN AND APPLICATION THEREOF | NANJING REJU THERAPEUTICS , INC. (CN) | 2023-08-03 | — | — | WO | claimed |
| WO-2023143463-A1 | FUSION PROTEIN AND APPLICATION THEREOF | NANJING REJU THERAPEUTICS , INC. (CN) | 2023-08-03 | — | — | WO | claimed |
| CN-116341385-A | Calculation method of spectral reflectance of blade | 沈阳农业大学 | 2023-06-27 | — | — | CN | claimed |
| CN-116322788-A | Cyclic RNA compositions and methods | 奥纳治疗公司 | 2023-06-23 | — | — | CN | claimed |
| US-11616371-B2 | Method for calculating parameter changing domain of loads under a case that guarantees constant locational marginal price in electricity market | STATE GRID FUJIAN ELECTRIC POWER RESEARCH INSTITUTE (CN) | 2023-03-28 | — | — | US | claimed |
| CN-112149214-B | Method for generating three-dimensional wrist arm supporting device by one-pole one-gear data driving model | 成都云铁智能交通科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| US-20220265767-A1 | HIGH CONCENTRATION CELL PENETRATING CASPASE INHIBITOR CONJUGATES, COMPOSITIONS AND METHODS THEREOF | UNIV COLUMBIA (US) | 2022-08-25 | — | — | US | claimed |
| WO-2022140118-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH MITOCHONDRIAL COMPLEX I DEFICIENCY USING CASPASE-9 SIGNALING PATHWAY INHIBITORS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-06-30 | — | — | WO | claimed |
| EP-3963067-A1 | GLUCONATE DEHYDRATASE ENZYMES AND RECOMBINANT CELLS | BP Corporation North America Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| CN-114139780-A | Coordinated optimization method and system for virtual power plant and power distribution network containing distributed power supply | 国网山西省电力公司电力科学研究院 | 2022-03-04 | — | — | CN | claimed |
| US-20220060028-A1 | METHOD FOR CALCULATING PARAMETER CHANGING DOMAIN OF LOADS UNDER A CASE THAT GUARANTEES CONSTANT LOCATIONAL MARGINAL PRICE IN ELECTRICITY MARKET | STATE GRID FUJIAN ELECTRIC POWER RESEARCH INSTITUTE (CN) | 2022-02-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027179-A1 | ANTI-SYNUCLEINOPATHY PEPTIDE AND METHODS TO TREAT NEURODEGENERATIVE DISEASES | SNCA, PARK7, LRRK2 | IL23R 2863/4885PTH1R 3264/4885KEAP1 3400/4885 |
| US-20240042015-A1 | CIRCULAR RNA COMPOSITIONS AND METHODS | U2AF1, RBM17, RBM22 | IL23R 405/4885PTH1R 1674/4885KEAP1 2482/4885 |
| US-20250387450-A1 | PROTEIN SCAFFOLDS FOR DISORDERED REGIONS | SPPL2B, SPPL2A, CRYZ | IL23R 1950/4885PTH1R 1771/4885KEAP1 3486/4885 |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | SARS1, RNMT, ACE2 | IL23R 723/4885PTH1R 639/4885KEAP1 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.